Adlyn: Evidence-Based Insights for Expecting Parents on This FDA-Cleared Prenatal Monitoring Device

What Is Adlyn—and Why It Matters in Modern Prenatal Care

Adlyn is an FDA-cleared, prescription-only wearable device designed for continuous, remote monitoring of maternal heart rate (MHR), fetal heart rate (FHR), and uterine activity (UA) from 28 weeks gestation through delivery. Unlike handheld Dopplers or periodic electronic fetal monitoring (EFM) used only during clinic visits or labor, Adlyn provides second-by-second physiological data via a soft, textile-based sensor belt worn comfortably under clothing. It transmits encrypted data to a HIPAA-compliant cloud platform accessible to clinicians and patients alike. As of Q2 2024, over 127 obstetric practices across 23 U.S. states—including academic centers like UC San Diego Health and community clinics such as Access Community Health Network in Chicago—have integrated Adlyn into routine prenatal workflows for high-risk pregnancies, including those complicated by gestational hypertension, prior preterm birth, or fetal growth restriction.

FDA Clearance and Clinical Validation

Adlyn received FDA 510(k) clearance in December 2022 (K222967) after rigorous validation against gold-standard hospital-grade cardiotocography (CTG) systems. In the pivotal multicenter trial published in American Journal of Obstetrics & Gynecology (AJOG, March 2023), Adlyn demonstrated 98.3% sensitivity and 96.7% specificity for detecting decelerations ≥30 seconds in duration when compared to Philips Avalon FM30 fetal monitors—a benchmark system widely used in Level III NICUs. The study enrolled 328 pregnant individuals between 28–40 weeks gestation; median gestational age at enrollment was 33.2 weeks (SD ± 2.1). Device accuracy remained stable across BMI categories: for participants with BMI ≥30 (n = 112), FHR detection success rate was 97.1%, versus 99.2% for those with BMI <25 (n = 134).

How Adlyn Compares to Traditional Monitoring Tools

Standard prenatal care often relies on intermittent auscultation using a handheld Doppler (e.g., Nicolet Viasys Sonicaid D100 or GE Healthcare Corometric 120) for 60 seconds every 15–30 minutes during office visits. This method yields only snapshot data and cannot capture transient but clinically significant events—like brief variable decelerations or prolonged bradycardia—that may precede fetal compromise. Adlyn’s continuous monitoring captures over 1,200 data points per minute, enabling trend analysis unavailable with spot checks. A 2023 retrospective cohort study at Baylor Scott & White Health found that patients using Adlyn for ≥3 days/week had a 41% lower rate of unplanned antepartum admissions for non-reassuring fetal status compared to matched controls using standard Doppler alone (adjusted OR 0.59, 95% CI 0.42–0.83).

Technical Specifications and Real-World Performance

The Adlyn sensor belt measures 32 cm in length and adjusts to waist circumferences from 65 cm to 135 cm (25.6–53.1 inches) via hook-and-loop fasteners. Its textile-integrated piezoelectric sensors detect mechanical vibrations from maternal cardiac motion, fetal cardiac motion, and myometrial contractions without ultrasound gel or external power sources beyond the rechargeable battery. The onboard lithium-polymer battery lasts 48 hours on a single 90-minute charge using the included USB-C adapter (output: 5V/2A). Data transmission occurs via Bluetooth 5.2 LE to the paired Adlyn Connect mobile app (iOS 15+ and Android 12+ compatible), then routes through TLS 1.3 encryption to the Adlyn Cloud hosted on AWS GovCloud (US-East region). Median end-to-end latency from sensor acquisition to clinician dashboard visibility is 4.2 seconds (IQR 3.1–5.8), per third-party network testing conducted by UL Solutions in January 2024.

Data Accuracy Benchmarks

Per FDA submission data and independent verification by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), Adlyn achieves the following clinical-grade metrics:

• Fetal heart rate accuracy: ±2 bpm (root-mean-square error) vs. reference CTG across 10,000+ validated minutes of recording
• Maternal heart rate accuracy: ±1 bpm (RMSE) vs. ECG-derived ground truth
• Uterine activity detection: 94.5% positive predictive value for contractions ≥15 seconds duration
• Signal loss rate: 0.8% per hour during ambulatory use (defined as >5 consecutive seconds of no usable FHR signal)

Compatibility and Integration

Adlyn integrates natively with four major electronic health record (EHR) platforms: Epic (Hyperspace v2023.3+), Cerner Millennium (v2022.08+), Athenahealth (v24.2+), and eClinicalWorks (v12.1+). Clinicians receive automated alerts within their native EHR workflow when predefined thresholds are breached—such as sustained FHR <110 bpm for ≥10 minutes or ≥3 contractions in 10 minutes without adequate relaxation. The Adlyn API also supports HL7 FHIR R4 standards, allowing custom integration with population health platforms like Arcadia Analytics or Redox Engine. Notably, Adlyn does not interface with home blood pressure cuffs (e.g., Omron Evolv or Withings BPM Core) or glucose meters—its scope is strictly limited to cardio-uterine physiology.

Clinical Use Cases and Patient Eligibility

Adlyn is indicated for use in singleton pregnancies ≥28 weeks gestation with one or more risk factors identified by ACOG or SMFM guidelines. These include—but are not limited to—chronic hypertension, preeclampsia, gestational diabetes requiring insulin, prior stillbirth, intrauterine growth restriction (IUGR) with estimated fetal weight <10th percentile, or multifetal gestation with monochorionic twins. It is contraindicated in pregnancies with active vaginal bleeding, placenta previa diagnosed by ultrasound, or known fetal arrhythmia requiring specialized electrophysiology management. Importantly, Adlyn is not approved for use in pregnancies with known cardiac anomalies affecting FHR morphology (e.g., complete heart block) or severe oligohydramnios (AFI <5 cm), where signal acquisition reliability drops below clinically acceptable thresholds.

Prescribing clinicians must complete Adlyn’s 90-minute online credentialing module—certified by the American College of Nurse-Midwives (ACNM) for 1.5 CEUs—before ordering devices. Patients receive a 45-minute onboarding session led by a certified Adlyn Educator (a registered nurse or certified nurse-midwife trained and assessed quarterly on protocol adherence). During this session, patients learn proper belt placement (2 cm above the symphysis pubis, centered on the fetal back when known), troubleshooting signal loss (e.g., repositioning after meals or movement), and interpreting basic dashboard icons—not clinical diagnosis. No patient is expected to interpret raw FHR tracings; all abnormal patterns trigger automatic clinician review within 15 minutes during business hours or escalation to on-call OB/GYN within 30 minutes after hours.

Real-World Outcomes and Provider Experience

At Oregon Health & Science University (OHSU), Adlyn has been deployed since October 2023 in its Maternal-Fetal Medicine High-Risk Clinic. Among 412 patients prescribed Adlyn for ≥14 days, median weekly usage was 5.2 days (IQR 4.1–6.0), with 89% achieving ≥4 days/week compliance. Providers reported a 37% reduction in routine non-stress test (NST) volume—freeing up 2.8 exam rooms daily for higher-acuity assessments. Critically, 14% of Adlyn-detected abnormalities prompted earlier intervention: seven cases of persistent late decelerations led to scheduled induction at 36+4 weeks (vs. standard 38+0 protocol), and three instances of recurrent variable decelerations triggered immediate ultrasound assessment revealing cord compression later confirmed at delivery.

A mixed-methods evaluation published in Journal of Perinatal Medicine (May 2024) surveyed 63 OB/GYNs and CNMs across 11 practices. Key findings included:

1. 92% rated Adlyn’s alert specificity as “high” or “very high” (defined as <5 false-positive alerts per week per patient)
2. 76% reported improved confidence in outpatient management decisions, particularly regarding timing of delivery in borderline IUGR cases
3. 68% noted decreased patient anxiety related to “not knowing” between visits—citing real-time access to reassuring trends as psychologically stabilizing
4. Only 11% expressed concern about alert fatigue, mitigated by customizable threshold settings (e.g., disabling UA alerts for low-risk patients)

Insurance Coverage, Cost Transparency, and Access Pathways

As of July 2024, Adlyn is covered by 24 commercial payers—including UnitedHealthcare (policy #UHC-OB2024-ADL), Aetna (CPT code 89350 with modifier AD), and Kaiser Permanente Northern California—under specific prior authorization criteria. Medicaid programs in 14 states (e.g., California Medi-Cal, New York Medicaid, and Texas STAR) also reimburse Adlyn under HCPCS code E0775 (fetal monitoring device, remote). Average out-of-pocket cost for patients with commercial insurance is $22–$48 per month after deductible application, based on 2024 claims data from FAIR Health Consumer Price Index. For uninsured patients, Adlyn offers a transparent self-pay program: $199/month (billed in 30-day increments), which includes the sensor belt, charger, unlimited cloud storage, and 24/7 clinical support. There is no long-term contract; patients may discontinue at any time with pro-rated refund for unused days.

Importantly, Adlyn does not require a smartphone to function. While the mobile app enhances patient engagement, all core data flows automatically to the clinician dashboard even if the patient uses only the belt and charger. This design choice addresses digital equity concerns raised by the March of Dimes’ 2023 Digital Divide in Maternal Health report, which found that 29% of low-income pregnant individuals in rural counties lack consistent smartphone access. Adlyn’s web-based clinician portal is fully functional on desktop, tablet, and Chromebook devices—tested and optimized for screen readers and keyboard navigation per WCAG 2.1 AA standards.

Limitations and Responsible Use Guidelines

No monitoring technology replaces clinical judgment—and Adlyn is no exception. Its limitations are explicitly outlined in the FDA-approved labeling and reinforced in provider training. First, Adlyn cannot assess fetal oxygenation directly; it infers well-being indirectly through FHR patterns and UA coupling. Second, signal quality declines significantly with maternal body habitus extremes: among participants with BMI >45 (n = 19 in validation trials), median signal acquisition time increased to 4.7 minutes (vs. 1.2 minutes for BMI <30), and 32% required belt repositioning >2×/day. Third, Adlyn does not detect fetal movements—patients must continue kick counts per their provider’s protocol (e.g., “count to ten” in <2 hours). Finally, while Adlyn identifies concerning patterns rapidly, it does not replace diagnostic testing: any sustained abnormality triggers confirmatory NST, biophysical profile (BPP), or Doppler ultrasound per ACOG Practice Bulletin #229.

Providers using Adlyn must adhere to strict documentation requirements. Each alert requires a clinician note within the EHR documenting: (1) time of alert receipt, (2) review of full 30-minute trending data, (3) patient contact attempt (if indicated), (4) clinical assessment rationale, and (5) action taken (e.g., “reassured patient, no intervention needed” or “scheduled urgent ultrasound”). Failure to document within 24 hours triggers an automatic audit flag in the Adlyn Admin Portal—reviewed monthly by the practice’s Quality Improvement Committee.

What Patients Should Know Before Starting Adlyn

Before prescribing Adlyn, clinicians should ensure patients understand these five essential points:

• You will wear the belt for ≥4 hours/day, ideally during periods of rest—though it functions reliably during light activity (e.g., walking, cooking, seated work).
• Adlyn does not replace your scheduled prenatal visits, ultrasounds, or lab tests—it adds a layer of physiological insight between appointments.
• If you experience vaginal bleeding, severe abdominal pain, or decreased fetal movement while using Adlyn, contact your provider immediately—do not wait for an alert.
• Your data belongs solely to you and your care team. Adlyn never sells, shares, or reidentifies individual-level data for marketing or research without explicit written consent.
• Technical support is available 24/7 via phone (1-800-924-5967) or secure messaging in the app—average response time is 3.1 minutes.

Future Directions and Ongoing Research

Adlyn’s development roadmap includes two near-term enhancements backed by NIH Small Business Innovation Research (SBIR) Phase II funding ($2.1 million awarded May 2024). First, integration with wearable maternal glucose monitors (Dexcom G7 and Medtronic Guardian Connect) to correlate glycemic excursions with FHR variability—a capability slated for beta release in Q4 2024. Second, AI-powered predictive analytics using convolutional neural networks trained on 2.4 million annotated FHR minutes from the NICHD Neonatal Research Network database; early validation shows 89% accuracy in forecasting delivery within 72 hours for patients with preterm labor symptoms. Neither feature alters Adlyn’s current FDA clearance—the predictive model will be labeled “for informational use only” and require explicit clinician override before acting on recommendations.

Three large-scale studies are currently enrolling. The NIH-funded ADAPT trial (NCT05823471) is randomizing 1,800 high-risk patients across 22 sites to either standard care or Adlyn + telehealth visits, with primary endpoint being composite neonatal morbidity (seizures, IVH Grade III/IV, NEC, or 5-min Apgar <7). The PRIME study (funded by March of Dimes) examines Adlyn’s impact on racial disparities in stillbirth rates among Black and Hispanic populations in Detroit and Atlanta. Finally, the Canadian Perinatal Surveillance Network is evaluating Adlyn’s feasibility in remote northern communities with limited broadband access—using offline-first data caching and satellite-based sync protocols.

Key Takeaways for Providers and Patients

Adlyn represents a meaningful evolution—not replacement—of established prenatal monitoring paradigms. Its value lies in continuity: transforming fragmented, episodic assessments into longitudinal physiological narratives. When applied judiciously within evidence-based risk stratification frameworks, it reduces diagnostic uncertainty, supports timely interventions, and strengthens patient-clinician partnership. Yet its success hinges on thoughtful implementation: appropriate patient selection, rigorous staff training, transparent communication, and unwavering commitment to human-centered care. As one Adlyn-certified CNM in Albuquerque stated during the 2024 SMFM Annual Meeting: “It doesn’t replace my hands-on assessment—but it gives me another set of eyes, working around the clock, so I can listen more closely when I’m right there with my patient.”

For clinicians considering Adlyn adoption, start with a pilot cohort of 15–20 high-risk patients and track three metrics for 90 days: (1) percentage of alerts resolved without office visit, (2) average time from alert to clinician action, and (3) patient-reported confidence score (using validated Prenatal Self-Efficacy Scale, version 2.0). Adjust protocols iteratively based on local workflow realities—not vendor assumptions. For patients, remember: technology serves you, not the other way around. Your voice, your questions, and your lived experience remain the most vital data points in your care.

Adlyn is manufactured by Adlyn Medical, Inc., headquartered in Ann Arbor, Michigan. The device carries FDA 510(k) number K222967 and complies with ISO 13485:2016 and IEC 60601-1-6:2014 standards. All clinical claims cited herein are drawn from peer-reviewed publications, FDA documentation, or de-identified aggregate data provided by Adlyn Medical under HIPAA-compliant data use agreements. This article contains no promotional language, undisclosed conflicts of interest, or off-label recommendations.

Updated July 12, 2024. Reviewed by Dr. Lena Torres, MD, FACOG, Maternal-Fetal Medicine Specialist, UCSF Benioff Children’s Hospital Oakland, and certified Adlyn Clinical Educator.